Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01841463
Title Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
Recruitment Suspended
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Piramal Enterprises Limited



Vemurafenib + Voruciclib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST